Charles River Laboratories International expects to boost its position in pharma manufacturing with a $212 million deal to buy Celsis International, a company that specializes in endotoxin and microbial detection (EMD).
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.
CRO giant Charles River Laboratories ended 2014 with a bang, boosting revenue by about 14% in the fourth quarter to close a deal-filled year.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.
Charles River Laboratories is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
Charles River Laboratories posted a slight increase in sales last quarter, crediting a rise in preclinical demand as it counts on some new acquisitions to brighten 2014.